Skip to main navigation Skip to search Skip to main content

COMBINING IMMUNE CHECKPOINT INHIBITOR WITH LENVATINIB PROLONGS SURVIVAL THAN LENVATINIB ALONE IN SORAFENIB-EXPERIENCED HEPATOCELLULAR CARCINOMA PATIENTS

Research output: Contribution to journalJournal Article peer-review

Original languageAmerican English
JournalHepatology
Volume72
StatePublished - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this